Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Autor: Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alayli FA; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Okrah K; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Drakaki A; University of California, Los Angeles , Los Angeles, CA, USA., Khalil DN; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Kummar S; Stanford University , Stanford, CA, USA., Khan SA; Stanford University , Stanford, CA, USA., Hodi FS; Dana-Farber Cancer Institute , Boston, MA, USA.; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute , Boston, MA, USA., Oh DY; University of California, San Francisco , San Francisco, CA, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Gautam S; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Meier SL; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA.; Stanford University , Stanford, CA, USA., Amouzgar M; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Pfeiffer SM; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Kageyama R; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Yang E; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Spasic M; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Tetzlaff MT; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hollmann TJ; Memorial Sloan Kettering Cancer Center , New York, NY, USA.; Bristol Myers Squibb , New York, NY, USA., Li Y; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Adamow M; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Wong P; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Moore JS; University of Pennsylvania , Philadelphia, PA, USA., Velichko S; Natera Inc. , Austin, TX, USA., Chen RO; Personalis Inc. , Fremont, CA, USA., Kumar D; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Bucktrout S; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Ibrahim R; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Dugan U; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Salvador L; Bristol Myers Squibb , New York, NY, USA., Hubbard-Lucey VM; Cancer Research Institute , New York, NY, USA., O'Donnell-Tormey J; Cancer Research Institute , New York, NY, USA., Santulli-Marotto S; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Butterfield LH; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Da Silva DM; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Fairchild J; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., LaVallee TM; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Padrón LJ; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.; Immunotherapy Platform, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2024 Oct 07; Vol. 221 (10). Date of Electronic Publication: 2024 Aug 27.

Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.

Autor: Chami P; Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon., Diab Y; Faculty of Medicine, University of Balamand, Beirut 1100, Lebanon., Khalil DN; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA., Azhari H; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA., Jarnagin WR; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA.; Department of Surgery, Weill Medical College, Cornell University, New York, NY 10021, USA., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA.; Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA., Harding JJ; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA.; Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA., Hajj J; Faculty of Medicine, University of Balamand, Beirut 1100, Lebanon., Ma J; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA., El Homsi M; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA., Reyngold M; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA., Crane C; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA., Hajj C; Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA.; New York Proton Center, New York, NY 10035, USA.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2023 Nov 26; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 26.

Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.

Autor: Khalil DN; Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. khalild@mskcc.org.; Parker Institute for Cancer Immunotherapy, New York, NY, USA. khalild@mskcc.org.; Weill Cornell Medicine, New York, NY, USA. khalild@mskcc.org., González-Albo IP; Akamis Bio Ltd, Abingdon, Oxford, UK., Rosen L; UCLA Medical Center, Los Angeles, CA, USA., Lillie T; Akamis Bio Ltd, Abingdon, Oxford, UK., Stacey A; Akamis Bio Ltd, Abingdon, Oxford, UK., Parfitt L; Akamis Bio Ltd, Abingdon, Oxford, UK., Soff GA; University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, FL, USA.

Publikováno v: Investigational new drugs [Invest New Drugs] 2023 Jun; Vol. 41 (3), pp. 539.

Rational development of combination therapies for biliary tract cancers.

Autor: Harding JJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA., Khalil DN; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA., Fabris L; Department of Molecular Medicine, University of Padua, and Division of General Medicine, Padua University-Hospital, Padua, Italy; Digestive Disease Section, Yale University School of Medicine, New Haven, CT, USA., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA. Electronic address: abou-alg@MSKCC.ORG.

Publikováno v: Journal of hepatology [J Hepatol] 2023 Jan; Vol. 78 (1), pp. 217-228. Date of Electronic Publication: 2022 Sep 20.